Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Amanda Jackson has expertise in ...

Vor Bio is the latest cell therapy company to reach the end of the road. The biotech is immediately winding down clinical and manufacturing operations and laying off almost all staff. Around 95% of ...

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...

Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune asset ...

Vor Biopharma is developing novel cell therapies for AML, with trem-cel showing early promise in clinical trials but facing significant funding challenges. Trem-cel aims to enhance relapse-free ...

Shares of Vor Bio VOR have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based ...

H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:VOR), highlighting the company’s “rebirth” following the in-licensing of telitacicept. On Thursday, the company announced a strategic licensing ...

Vor Biopharma Inc. (NASDAQ:VOR) saw its stock climb Thursday following a strategic licensing agreement and a major capital raise to support its push into autoimmune therapies. The developments mark a ...

WENZHOU, China, July 30, 2018 (GLOBE NEWSWIRE) -- Hebron Technology Co., Ltd. ("Hebron" or the "Company") (Nasdaq: HEBT), a developer, manufacturer and installer of valves and pipe fittings for use in ...